Veradermics IPO Pops Above Range as Eli Lilly Lines Up a 5% Stake Play
Veradermics priced its upsized IPO at $17 per share, raising about $256.3 million ahead of its NYSE debut under the ticker “MANE” on Feb. 4. Eli Lilly disclosed plans to acquire up to 4.9% of post-IPO shares, though the move is not binding. Veradermics sold 15,077,647 new shares, valuing the company at roughly $596 million.
